COVI-AMG

BIOLOGICAL4 trials

Sponsors

Sorrento Therapeutics, Inc.

Conditions

Covid19

Phase 1

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19

WithdrawnNCT04584697

Sorrento Therapeutics, Inc.Covid19

Start: 2020-12-31End: 2021-04-30Updated: 2021-02-12

Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19

WithdrawnNCT04738175

Sorrento Therapeutics, Inc.Covid19

Start: 2021-04-30End: 2021-11-30Updated: 2022-02-25

Phase 2

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms

WithdrawnNCT04734860

Sorrento Therapeutics, Inc.Covid19

Start: 2021-04-30End: 2021-11-30Updated: 2022-02-25

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19

WithdrawnNCT04771351

Sorrento Therapeutics, Inc.Covid19

Start: 2021-04-30End: 2021-10-31Updated: 2022-08-16